Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 7/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | USP5 | P45974 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664098 | 0.86 | ADRA1A (0.54) | SCD5ADRA1AHCAR2NPC1SCD | |
| SCHEMBL3664719 | 0.86 | MYC (0.41) | ADRA1AHDAC2USP5NPC1KMO | |
| SCHEMBL3664510 | 0.85 | HTR2C (0.42) | ADRA1AUSP5KMOCHRM4 | |
| SCHEMBL3664232 | 0.85 | HDAC2 (0.44) | ADRA1AHDAC2HCAR2NPC1 | |
| Hydrochloric Acid SCHEMBL4090130 | 0.85 | ADRA1A (0.52) | SCD5ADRA1AHCAR2NPC1SCD | |
| SCHEMBL4026557 | 0.84 | USP5 (0.40) | SCD5ADRA1AHDAC2HCAR2USP5 | |
| SCHEMBL3664678 | 0.83 | ADRA1A (0.48) | ADRA1AUSP5CHRM4 | |
| Hydrochloric Acid SCHEMBL4093442 | 0.82 | ADRA1A (0.47) | ADRA1AUSP5CHRM4 | |
| SCHEMBL3665069 | 0.81 | HTR7 (0.39) | ADRA1AHDAC2 | |
| SCHEMBL4027548 | 0.81 | HCAR2 (0.47) | SCD5HDAC2HCAR2KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288424-B2 | Substituted tetrahydroimidazopyridine compounds and the use thereof in the treatment of pain and other conditions | GRUENENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-2235013-B1 | SUBSTITUTED TETRAHYDROIMIDAZOPYRIDINE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICALS | GRUENENTHAL GMBH (DE) | 2012-08-01 | — | — | EP | disclosed |
| EP-2083009-A1 | Substituted tetrahydroimidazopyridine compounds and their use in medicine | Grünenthal GmbH (DE) | 2009-07-29 | — | — | EP | disclosed |
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | HRH4, TRPV1, QDPR | SCD5 4289/4885ADRA1A 517/4885HDAC2 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.